Targeting the DNA damage response (DDR) by natural compounds

被引:20
|
作者
van Stuijvenberg, Jana [1 ]
Proksch, Peter [2 ]
Fritz, Gerhard [1 ]
机构
[1] Heinrich Heine Univ Dusseldorf, Med Fac, Inst Toxicol, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Inst Pharmaceut Biol & Biotechnol, Univ Str 1, D-40225 Dusseldorf, Germany
关键词
DNA damage response; Cell death; Natural compounds; Tumor cell resistance; REDUCTASE INHIBITORS STATINS; MARINE SPONGE METABOLITE; DOUBLE-STRAND BREAKS; CANCER-CELLS; ANTICANCER ACTIVITY; PROTEIN-KINASE; IN-VITRO; APOPTOSIS; ARTESUNATE; BEAUVERICIN;
D O I
10.1016/j.bmc.2019.115279
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Natural compounds (NC) are an important source of anticancer drugs. The genomic DNA of tumor cells is a major target of conventional anticancer therapeutics (cAT). DNA damage elicits a complex stress response programme termed DNA damage response (DDR), with the PI3-like kinase ATM and ATR being the key regulators. Since the DDR coordinates mechanisms of DNA repair and apoptosis, hence regulating the balance between death and survival, it is an attractive target of novel anticancer strategies. The aim of the study was to identify natural compounds derived from endophytic fungi, lichens, marine sponges or plants that interfere with mechanisms of the DDR. To this end, the cytotoxic and DDR modulating potency of 296 natural compounds, used alone or in combination with the cAT cisplatin (Cis) and doxorubicin (Doxo) was investigated by fluorescencebased analysis of the ATM/ATR-catalyzed S139 phosphorylation of histone 2AX (gamma H2AX), a surrogate marker of DNA damage-triggered DDR. After initial screening, a total of ten natural compounds were identified that were toxic in pancreatic carcinoma cells and activated the DDR on their own and/or promoted the DDR if used in combination with cAT. Their mode of action was shown to be independent of drug transport mechanisms. Based on their chemical structures, DDR modulatory activity and published data we suggest the marine NC 5-epi-nakijiquinone Q and 5-epi-ilimaquinone as well as the fungal compound secalonic acid F as most promising NC-based drug candidates for future synthesis of DDR-modulating chemical derivatives and their preclinical in vitro and in vivo testing.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
    Flem-Karlsen, Karine
    McFadden, Erin
    Omar, Nasrin
    Haugen, Mads H.
    Oy, Geir Frode
    Ryder, Truls
    Gullestad, Hans Petter
    Hermann, Robert
    Maelandsmo, Gunhild Mari
    Florenes, Vivi Ann
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (03) : 895 - 905
  • [22] Wip1 downregulation conserves truncated DNA damage response (DDR) in mitosis
    Vaz, Bruno
    Ramadan, Kristijan
    CELL CYCLE, 2013, 12 (03) : 391 - 392
  • [23] Why Human Papillomaviruses Activate the DNA Damage Response (DDR) and How Cellular and Viral Replication Persists in the Presence of DDR Signaling
    Bristol, Molly L.
    Das, Dipon
    Morgan, Iain M.
    VIRUSES-BASEL, 2017, 9 (10):
  • [24] Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma
    Magni, Martina
    Paolizzi, Chiara
    Monfrini, Chiara
    Vella, Cristina
    Corradini, Paolo
    Carniti, Cristiana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [25] DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
    Roos, Wynand P.
    Kaina, Bernd
    CANCER LETTERS, 2013, 332 (02) : 237 - 248
  • [26] Targeting DNA damage response: Threshold, chromatin landscape and beyond
    Gonfloni, Stefania
    PHARMACOLOGY & THERAPEUTICS, 2013, 138 (01) : 46 - 52
  • [27] Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
    Southgate, Harriet E. D.
    Chen, Lindi
    Curtin, Nicola J.
    Tweddle, Deborah A.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [28] Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
    Huang, Jau-Ling
    Chang, Yu-Tzu
    Hong, Zhen-Yang
    Lin, Chang-Shen
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [29] Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
    Bukhari, Amirali B.
    Chan, Gordon K.
    Gamper, Armin M.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
    Dreyer, Stephan B.
    Upstill-Goddard, Rosie
    Paulus-Hock, Viola
    Paris, Clara
    Lampraki, Eirini-Maria
    Dray, Eloise
    Serrels, Bryan
    Caligiuri, Giuseppina
    Rebus, Selma
    Plenker, Dennis
    Galluzzo, Zachary
    Brunton, Holly
    Cunningham, Richard
    Tesson, Mathias
    Nourse, Craig
    Bailey, Ulla-Maja
    Jones, Marc
    Moran-Jones, Kim
    Wright, Derek W.
    Duthie, Fraser
    Oien, Karin
    Evers, Lisa
    McKay, Colin J.
    McGregor, Grant A.
    Gulati, Aditi
    Brough, Rachel
    Bajrami, Ilirjana
    Pettitt, Stephan
    Dziubinski, Michele L.
    Candido, Juliana
    Balkwill, Frances
    Barry, Simon T.
    Grutzmann, Robert
    Rahib, Lola
    Johns, Amber
    Pajic, Marina
    Froeling, Fieke E. M.
    Beer, Phillip
    Musgrove, Elizabeth A.
    Petersen, Gloria M.
    Ashworth, Alan
    Frame, Margaret C.
    Crawford, Howard C.
    Simeone, Diane M.
    Lord, Chris
    Mukhopadhyay, Debabrata
    Pilarsky, Christian
    Tuveson, David A.
    Cooke, Susanna L.
    Jamieson, Nigel B.
    GASTROENTEROLOGY, 2021, 160 (01) : 362 - +